
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. has reported a year-over-year growth of 2% in EsoGuard test volume for Q3 2025, reaching 2,841 tests, indicating a steady demand for its diagnostic products. The company's ongoing initiatives to broaden coverage for EsoGuard through various payers, including Medicare, are anticipated to boost revenue growth significantly as it commercializes its offerings further. Additionally, a positive outcome from the recent MolDX CAC meeting suggests favorable prospects for Medicare coverage, which could enhance the company’s market penetration and potential for revenue growth, offering a compelling upside.
Bears say
The financial health of Lucid Diagnostics Inc. appears tenuous, as the company reported a consensus revenue miss for 3Q25, indicating potential challenges in market adoption of its flagship product, EsoGuard. The pro forma net loss of $10.3 million, coupled with a stable cash burn and only $47 million in pro forma cash, raises concerns regarding the company's liquidity and operational efficiency. Additionally, ongoing risks include slow adoption rates, potential difficulties in obtaining insurance reimbursements, and increased competition, all contributing to a broader negative outlook on the company's financial viability.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares